| Trade name(s) | BONEFOS® |
| Classification | CALCIUM REGULATING AGENT BIPHOSPHONATE |
| Indication(s) | Hypercalcaemia of malignancy. |
| Presentation | 300mg in 5mL, ampoule. |
| Storage | Store between 15 and 25°C. Protect from light. |
| Reconstitution | Not required. Dilute further before use. |
| Stability | Contains no bacteriostat. Discard any unused solution. |
| Compatible Fluid(s) NS; G5W |
| Incompatible Fluid(s) HARTMANN'S; RINGER'S Solutions containing calcium. |
| Incompatible Drug(s) Avoid mixing in solution with any other drugs. |
| Administration (Mode) IVI: INTERMITTENT INFUSION |
| Intravenous Concentration Intermittent Infusion: 300mg in 500mL. |
| Intravenous Rate Intermittent Infusion: Infuse over at least 3 hours. |
| Manner of Administration and Dosage Guide Adult : Hypercalcaemia of malignancy: 300mg administered daily until normocalcaemia is achieved. Duration of therapy is between 3 to 5 days and not usually beyond 7 days. Alternatively, 1.5grams as a single dose given over 4 hours. Dosage should be individualised and based on clinical response. Consider administration in divided doses if adverse gastrointestinal effects occur. |
| Adverse Effect(s) Hypocalcaemia, nausea, vomiting, diarrhoea, epigastric pain, renal damage and dysfunction, elevated parathyroid hormone, elevated liver enzymes, skin rashes |
| Precaution(s) Check for hypersensitivity to clodronate before administration. Avoid bolus or rapid injection. Monitor serum electrolytes, white cell count, hepatic and renal functions. Consider dosage modification in renal dysfunction and cease therapy if renal function deteriorates markedly. Avoid in patients with moderate to severe renal impairment or severe inflammatory gastrointestinal disease. Use with caution in patients with a history of asthma or atopy. Do not give with other biphosphonates and exercise care with concurrent use of other anti-hypercalcaemic agents and aminoglycosides due to possible severe hypocalcaemia. |
| Additional Information Rehydration with sodium chloride 0.9% w/v should be considered prior to the commencement of therapy and during treatment. The patient may also require oral therapy for long term treatment. Symptomatic hypocalcaemia may be reversed by the administration of calcium gluconate. Hdx: No data. Pdx: No data. Sodium: Negligible. Displacement: Negligible. ©1997 JBC Handbook™ 4th edition ISBN: 0 646 326 767 |